Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

William Blair Initiates Coverage On Mersana Therapeutics with Outperform Rating

Author: Benzinga Newsdesk | February 06, 2025 07:09am
William Blair analyst Andy Hsieh initiates coverage on Mersana Therapeutics (NASDAQ:MRSN) with a Outperform rating.

Posted In: MRSN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist